GORE VSX 20-03 – Evaluation of the use of the “GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface” (VSX), a device manufactured by W. L. Gore & Associates, Inc. (“Device”)

FAR-RMS – FRONTLINE AND RELAPSED RHABDOMYOSARCOMA: FAR-RMS clinical trial. EudraCT Nr. 2018-000515-24; ClinicalTrials.gov Identifier: NCT04625907

ZEISS – Certifications and Foundations of Safe Machine Learning Systems in Healthcare

Refernzkundenvertrag – Siemens Refernzkundenvertrag

SCHI 498/11-2

Melanom – Ein Ganzkörper Radiomics ansatz zur Outcome-Vorhersage in Patienten mit metastasiertem Melanom unter Systemtherapie

Age – Bestimmung des organ-spezifischen biologischen Alters anhand von Ganzkörper MRT-Daten aus der NAKO MR Studie

Muscle – Bildmorphologische Biomarker der menschlichen Skelettmuskulatur (Muskelmasse, morphologische und Textureigenschaften von Muskelgruppen desKörperstamms, Oberschenkels und Oberarms) bei Sarkopenie und kardiometabolischen Erkrankungen

Melanom – Ein Ganzkörper Radiomics Ansatz zur Outcome-Vorhersage in Patienten mit metastasiertem Melanom unter Systemtherapie

DFG 1042/2-1 – “Numerische Multiphysikmodellierung des postprandialen menschlichen Magens“

PET-LIT – Metastasierte Melanompatienten unter Immuntherapie: Überwachung des Therapieerfolges mittels Liquid Biopsy und PET/CT im Rahmeneiner prospektiven Studie (PET-LIT)

Euroscreen ESN 364 – A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids

monarcHER – A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer

D419LC00001 – A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients